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Accepted 5 March 2010AbstractObjective: Primary fallopian tube carcinoma is one of the least common gynecological cancers and is difficult to diagnose preoperatively. We
aimed to analyze the clinicopathological characteristics of this rare disease and to identify the prognostic factors predicting prognosis.
Materials and Methods: Twelve cases of primary fallopian tube carcinoma that had been diagnosed and treated in Kaohsiung Chang Gung
Memorial Hospital between July 1986 and December 2005 were retrospectively reviewed. Factors, including age, gravidity, parity, stage,
surgical intervention, pathological findings, relapse, and survival, were analyzed.
Results: The median age of the 12 cases was 54 years (range, 32e67 years), whereas the median follow-up time was 38 months. None of the 12
cases were diagnosed preoperatively. Preoperative diagnoses were adnexal mass of unknown nature in six (50%), tubo-ovarian abscess in three
(25%), ovarian carcinoma in two (16.7%), and endometrioma in one (8.3%) cases. Two patients (16.7%) had experienced the typical symptom of
watery vaginal discharge. Three patients (25%) were in Stage I, three (25%) in Stage II, four (33.3%) in Stage III, and two (16.7%) were
unstaged. Nine patients had received postoperative platinum-based adjuvant chemotherapy. The 5-year disease-free survival rate was 64%. On
evaluating the correlation between clinicopathological parameters and survival, only the Federation of Gynecology and Obstetrics stage
( p¼ 0.017) was a significant prognostic factor.
Conclusion: Although preoperative diagnosis of fallopian tube carcinoma is difficult, still 16.7% of our patients experienced the typical symptom
suggestive of tubal carcinoma. Prognostic factors associated with fallopian tube cancer were similar to those of epithelial ovarian cancer.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Primary fallopian tube carcinoma (PFTC) is one of the
least common gynecological cancers and is difficult to diag-
nose preoperatively. Fewer than 5% of patients are accurately
diagnosed before surgical exploration [1]. Although the
symptom complex of “hydrops tubae profluence” is considered* Corresponding author. Division of Gynecologic Oncology, Department
Obstetrics and Gynecology, Chang Gung Memorial HospitaldKaohsiung
Medical Center, 123, Ta Pei Road, Niao Sung Hsiang, Kaohsiung County 883,
Taiwan.
E-mail address: tedycou@gmail.com (H. Lin).
1028-4559/$ - see front matter Copyright  2011, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2011.01.031pathognomonic for PFTC, it is rarely encountered. Rarely,
patients with PFTC are diagnosed preoperatively by a positive
Papanicolaou smear, negative endometrial/endocervical curet-
tage, and the presence of a pelvic mass on ultrasonography
[2,3]. This rare disease has traditionally been treated in the
same manner as epithelial ovarian cancer; however, the prog-
nosis for PFTC is variable. Some investigators report that the
prognosis with PFTC is better than that with ovarian cancer,
whereas other investigators claim that it is worse for PFTC
[4,5]. The purpose of this study was to review the experience
of managing PFTC in Kaohsiung Chang Gung Memorial
Hospital and to identify the prognostic factors.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Fig. 1. Five-year disease-free survival.
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Patients with fallopian tube carcinoma treated between
July 1986 and December 2005 were identified in the cancer
registry databases at Kaohsiung Chang Gung Memorial
Hospital. In total, 15 patients were identified over this period.
The pathology slides from these 15 patients were retrieved and
retrospectively reviewed by one of the study authors (C.-C.
Huang) to confirm the diagnosis of PFTC based on the criteria
proposed by Hu et al [6]. Epithelial ovarian cancer with tubal
metastasis was diagnosed in three patients instead of PFTC.
Medical records for the remaining 12 patients were then
evaluated for information regarding age, gravidity and parity,
clinical presentation, preoperative diagnosis, stage of disease,
surgical intervention, pathological findings, relapse, and
survival. International Federation of Gynecology and Obstet-
rics (FIGO) staging for fallopian tube cancer was completed
whenever possible using surgical and pathological findings
extracted from the patients’ surgical records.
Univariate and multivariate analyses of possible prognostic
factors (age, gravidity, parity, FIGO stage, histological type,
tumor differentiation, and residual tumor) were performed.
KaplaneMeier life table analysis was used to generate
survival curves. Survival based on categorical variables was
compared using the log-rank test (univariate analysis),
whereas multivariate analysis was performed using the Cox
proportional hazards regression model. All statistical analyses
were performed with the SPSS for Windows version 11.5
program (SPSS Asia Pacific Pte. Ltd., Singapore). A p value
less than 0.05 was considered significant.
Results
The median age at the time of diagnosis was 54 years
(range, 32e67 years). Only one of the 12 patients diagnosed
with PFTC was nulliparous. None of the included patients had
either hysterectomies or tubal sterilization. Six (50%) of the
included patients were postmenopausal (i.e. cessation of
menstruation for at least 1 year) and no patient had a family
history of breast, uterine, colon, and/or ovarian cancer in
a first-degree relative.
The most common presenting symptoms were abdominal
pain (50.0%), watery vaginal discharge (16.7%), vaginal
bleeding (16.7%), leukorrhea (8.3%), and flank pain (8.3%).
None of the 12 patients was correctly diagnosed preopera-
tively. Instead, preoperative diagnoses included adnexal mass
of unknown nature (n¼ 6, 50.0%); tubo-ovarian abscess
(n¼ 3, 25.0%); ovarian carcinoma (n¼ 2, 16.7%); and ovarian
endometrioma (n¼ 1, 8.3%).
Four (36.7%) tumors were adenocarcinoma of serous type,
whereas seven (63.6%) were non-serous (4 poorly differenti-
ated, 3 endometrioid type, and 1 mucinous type) tumors and
one was a mixed-type tumor. Seven patients had preoperative
serum CA125 (enzyme immunoradiometric assay) levels
evaluated. Antigen levels were greater than 35 U/mL in four
patients: three patients in Stage III disease and one patient in
Stage I/II disease.Complete surgical staging (including lymphadenectomy)
was achieved in 10 patients. Of these, three were in Stage I,
three were in Stage II, and four were in Stage III. All 12
patients had surgical removal of their tumor as primary
therapy. Furthermore, nine patients received platinum-based
chemotherapy [7 with cisplatin (Kemoplat, India) and cyclo-
phosphamide (Endoxan, Germany) and 2 with paclitaxel
(Phyxol, Taiwan) and cisplatin].
The median follow-up time was 38 months (range, 18e210
months). Eight patients had no recurrence in the follow-up
period, whereas the remaining four patients did have disease
recurrence and finally succumbed to the disease. The overall
5-year disease-free survival rate was 64% (Fig. 1). By log-rank
univariate analysis, survival was significantly related to the
FIGO stage (Stage I or II vs. Stage III, p¼ 0.017; Fig. 2). The
clinicopathological factors associated with 5-year disease-free
survival have been summarized in Table 1. In the Cox
regression model, the FIGO stage had only a marginal level of
significance. It is likely that this analysis was affected by the
small number of cases included in this study.
Discussion
PFTC is a very rare disease, accounting for less than 1% of
all gynecological malignancies [7]. Therefore, unlike ovarian
cancer, fallopian tube cancer is not routinely suspected in
a patient with a complex pelvic mass. Preoperative diagnosis
of tubo-ovarian abscess was made in 25% of the 12 patients
included in this study, similar to previously published studies
[8e10]. Although accurate preoperative diagnosis is difficult,
PFTC reportedly is most often diagnosed in an earlier stage of
disease than its ovarian carcinoma counterpart [11,12]. This
might be because of many PFTC patients experiencing lower
abdominal pain as a result of tubal dilatation and because of
the development of an abnormal watery vaginal discharge.
With modern advances in medical imaging technologies,
the successful preoperative diagnosis of PFTC using trans-
vaginal color and pulsed Doppler ultrasound has been reported
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Fig. 2. Five-year disease-free survival according to the Federation of Gyne-
cology and Obstetrics stage.
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cystic lesion of the fallopian tube with papillary projections,
distinct from the ovary and uterus, in association with a low
vascular impedance, might lead to a suspicion of tubal
malignancy [13].
Etiological factors for the development of PFTC have not
been clearly defined. Although some investigators have sug-
gested that primary carcinoma of the fallopian tube shares
several biological and clinical features with ovarian carcinoma
[14,15], we did not find an increased number of nulliparous
women among our patient cohort. Another etiological factor
that probably relates to fallopian tube carcinoma is chronicTable 1
Predictors for survival in univariate analysis
Factor n (%) 5-yr survival (%) p (log rank)
Age (yr)
<50 4 (33.3) 50 0.658
>50 8 (67.7) 75
Gravida
2 6 (50) 42.9 0.079
>2 6 (50) 100
Parity
2 8 (66.7) 57.4 0.226
>2 4 (33.3) 100
Federation of Gynecology and Obstetrics stage
I, II 6 (60) 83.3 0.017
III 4 (40) 25.0
Histology
Serous 4 (36.7) 75.0 0.869
Non-serous 7 (63.6) 68.6
Differentiation
Grade I/II 7 (58.3) 57.1 0.536
Grade III 5 (41.7) 75.0
Residual tumor
No 9 (75) 74.1 0.178
Yes 3 (25) 33.3
Significant if p< 0.05.tubal inflammation [16]. Several previous reports and ours
found a higher incidence of tubo-ovarian abscess in fallopian
tubes, concurrent with carcinoma; however, the exact causal
relationship between the abscess and carcinoma is unknown. It
is unclear whether PFTC and epithelial ovarian carcinomas
share the same etiological factors. One recent publication
reported that pelvic serous carcinoma could follow a defined
precursor of the distal fallopian tube that has been present for
some time [17].
Initial management of PFTC is surgical, and the FIGO
staging system requires a surgical extirpation similar to that
mandated for ovarian carcinoma. Postoperative chemotherapy
with a platinum-based regimen is usually recommended in
patients, except in those diagnosed with well-differentiated
Stage IA and B disease. In the study reported herein, two
patients did not receive standard surgical staging procedures
owing to the undiagnosed tubal carcinoma during surgery. The
need for adjuvant chemotherapy in such apparent early-stage
disease was therefore very difficult to assess. Nonetheless,
patients are advised to undergo chemotherapy because there
may be up to a 33% incidence of upstaging [18].
With the introduction of cisplatin-containing chemotherapy
regimens, an objective response rate of about 80% can be
achieved in patients with advanced disease [19,20]. In the
patients included in this study, three Stage III patients had
residual disease after surgical treatment. Of these, two had
measurable disease, and both achieved complete clinical
response after six courses of chemotherapy. Unfortunately, the
response duration was quite short: only 2 months and 10
months. Both patients finally succumbed to the disease.
The 5-year disease-free survival rate for all stages of PFTC
varies, ranging from a low of 22% to a high of 57% [14,15].
Differences in stage distribution could contribute to this large
discrepancy, because FIGO stage is the most consistent
prognostic factor associated with survival [11,12,14,15,21,22].
In the patients included in this series, eight of the patients’
cancers (66.7%) were confined to the pelvis, which likely
explains the relatively high survival rate. Other useful prog-
nostic factors, although less consistent than FIGO stage,
include patient age at time of diagnosis, residual tumor after
initial surgery, and histological grading [5,12,15]. Although
the current study failed to demonstrate that patient age was an
independent prognostic factor for survival, the median age at
time of diagnosis in the 12 patients was 54 years, which was
much lesser than that in the largest report by Rosen et al [12].
In their study, the mean age of 143 patients was 62.5 years.
The lesser patient age in our series might also help explain the
better survival rate in the present study.
Despite the application of appropriate statistical techniques
regarding the risk factors for tubal cancers, multivariate
analysis is not adequate for the analysis of small numbers of
cases. In the study presented earlier, only the stage was
a significant prognostic factor predicting survival. Histology,
differentiation, and residual tumor were not significant prog-
nostic factors; however, these three factors are widely
considered by oncologists to be effective factors in the prog-
nosis of ovarian cancers. As mentioned earlier, tubal cancer
144 Y.-C. Ou et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 141e144reportedly is often diagnosed in an earlier stage than ovarian
carcinoma. Nonetheless, tubal cancers are still commonly
diagnosed with intraperitoneal dissemination. Prognosis of
tubal cancers seems to be better than that of ovarian cancers at
each stage because the histology of this malignancy is usually
of the serous type that is sensitive to chemotherapy [4].
Because only four cases of serous-type tumors were included
in this study, this small inclusion would explain the lack of
significance for prognostic factors. Tubal cancer is a rare type
of gynecological malignancy, and a large multicenter study
will help establish the prognostic risk factors.
In conclusion, the presence of abdominal pain in a patient
with PFTC is highly significant because cancers of the ovary,
endometrium, and cervix do not typically cause abdominal
pain until their diagnosis is all too obvious. A diagnosis of
PFTC should be considered in patients complaining of lower
abdominal pain in association with vaginal bleeding/watery
discharge or with a tubo-ovarian abscess. The etiology of
fallopian tube and epithelial ovarian carcinomas is not well
established, but both cancers should be managed in the same
manner. The clinicopathological prognostic factors of PFTC
are almost identical to those of epithelial ovarian carcinoma.References
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